Cite
HARVARD Citation
Fangusaro, J. et al. (2022). Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro-oncology. 24 (8), p. 1404. [Online].